Stratos Genomics, a Seattle-based biotech company, has raised $10 million of a $16.3 million series B round. CEO Allan Stephan confirmed the new funding with us today, but wouldn’t disclose investors.
Founded in 2007, Stratos Genomics is a spin-off of Seattle-based Stratos Group. The company builds technology called Sequencing By Expansion, or “SBX,” which converts DNA into more easily-read polymer, making it cheaper and faster to sequence DNA.
Stratos Genomics had previously raised $10.1 million, and the Series B round will push total funding to more than $26 million.
This is the latest capital coming into the Puget Sound biotech industry. Tacoma, Wash.-based Revalesio just raised $13.5 million of a $40 million round for its technology that can helps treat inflammatory diseases; cancer research startup Juno Therapeutics raised a whopping $176 million series A investment last month; and Integrated Diagnostics, a Seattle company developing blood-based proteomic tests, raised a $47.25 million round a few weeks ago.
